TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Oedematous Lower Limb Subcutaneous Drainage in Palliative Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* palliative care patients~* Karnofsky Scale \< 50%~* Uni or bilateral lower limb oedema even if associated with lumbar or pelvi-scrotal oedema or ascitis whatever etiology involved (cancer, organ failure, hypoalbuminemia...)~* Effective Social security regimen affiliation~* Signed informed consent~Exclusion Criteria:~* Refusal to take part in the study~* Local anesthesic contraindication~* Infected skin lesions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oedematous lower limb subcutaneous drainage (Type: EXPERIMENTAL): In case of lymphoedema in palliative situation, a subcutaneous drainage can be performed. It is a simple method, easy to use. After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PRISMA-PET - Primary Staging of Prostate Cancer With PSMA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has given informed consent to participate~* Can read and understand provided patient information material in Danish~* Biopsy verified PCa~* Any, some, or all of the following features:~  * Prostatic Specific Antigen (PSA) ≥ 20 ng/ml OR~ * Gleason Score ≥ 4+3 OR~ * Tumor stage clinically judged T2c cancer (cT2c) or above as determined by digital rectal exploration and/or transrectal ultrasonography~ * Suspicion of metastases clinically based on other findings~* Prostatic Specific Antigen (PSA) ≤ 200 ng/ml~* Staging by imaging warranted~Exclusion Criteria:~* Consent not given~* Inability to read and/or understand provided patient information in Danish~* Previously given consent but withdrawn for any reason~* Staging by imaging not warranted as judged clinically~* Allergy towards contents in the tracer solution

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A) Conventional Imaging (Type: NO_INTERVENTION): Conventional Imaging with NaF (sodium fluoride)-PET/CT used for staging
- B) Interventional Imaging (Type: EXPERIMENTAL): Staging with the interventional18F-PSMA-1007 PET/CT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Micafungin Salvage Mono-therapy in Invasive Aspergillosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with HSCT, acute leukaemia or myelodysplastic syndrome, with proven (probable only in case of pulmonary aspergillosis) invasive aspergillosis and refractory or intolerant to amphotericin B or voriconazole products~Exclusion Criteria:~* Patients with allergic bronchopulmonary aspergillosis, chronic pulmonary aspergillosis, aspergilloma, sinus aspergillosis or external otitis; patient with previous salvage therapy for the current episode of fungal infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): infusion for 3-12 weeks
- 2 (Type: EXPERIMENTAL): infusion for 3-12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years old~* Admitted for acute decompensated HF with left ventricular ejection fraction (LVEF) \<40%~* Refractory fluid overload:~* Unresponsive (\<500 mL net negative over previous 24 hours) AND ineffective diuresis (determined by HF team) to moderate intensity push or low intensity continuous infusion loop diuretic (80 mg IV furosemide or equivalent bumetanide dose of 4 mg)~* English or Spanish-speaking subjects~* Willing and able to comply with study procedures~Exclusion Criteria:~* Baseline thiazide use prior to admission or prior to study enrollment~* Renal replacement therapies (RRT) or glomerular filtration rate (GFR) \<30 mL/min at the time of enrollment~* Pregnant women~* Cognitive impairment~* Prisoners~* Left ventricular assist devices (LVAD) or temporary mechanical circulatory support devices~* History of cardiac transplant~* Reported allergy to thiazides~* No enteral access or unable to take medications enterally~* Palliative diuretics~* Systolic blood pressure (SBP) \<90 mm Hg prior to randomization~* Patients receiving concomitant lithium therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metolazone (Type: ACTIVE_COMPARATOR): Metolazone 5 mg by mouth once daily for 2 days
- Chlorothiazide (Type: ACTIVE_COMPARATOR): Chlorothiazide 500 mg IV once daily for 2 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* aged 12-21 years~* chronic (\>3 months)symptoms of orthostatic intolerance (including but not limited to lightheadedness, syncope, headache, fatigue, weakness, sweating, nausea and palpitations)~* symptomatic orthostatic heart rate increase of greater than or equal to 40 beats per minute during a 10 minute 70 degree head up tilt study~* presence of non-anemic iron deficiency, defined as serum ferritin level less than or equal to 20 ug/L with normal hemoglobin~Exclusion criteria~* orthostatic hypotension within 3 minutes of 70 degree head up tilt~* pregnant or lactating females~* presence of other organ failure or systemic illness that can affect autonomic function~* concurrent medication therapy with anticholinergic, alpha-adrenergic antagonists, beta-adrenergic antagonists unless medication is held for five half-lives prior to study~* laboratory evidence of anemia or iron overload~* personal history of hematochromatosis or first degree relative with hematochromatosis~* known sensitivity to Venofer (TM) or other intravenous iron preparations

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Iron infusion (Type: EXPERIMENTAL): Iron Sucrose (Venofer (R))
- Normal saline infusion (Type: PLACEBO_COMPARATOR): Equal volume to intervention of normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on Atherosclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects, ≥ 30 years old with either known atherosclerotic coronary or vascular disease OR coronary risk equivalents defined as either:~  * diabetes mellitus,~ * multiple coronary risk factors with a Framingham Risk Score \> 2% per year, or~ * an elevated coronary calcium score (\> 400 for men, \> 200 for women)~* Currently being treated with a statin (Simvastatin 20 mg/d or its equivalent) as monotherapy for treatment of hyperlipidemia~* Recent lipids (within the past 3 months without interval change in the statin regimen) showing both: LDL-C \< 100 mg/dL and HDL-C \< 50 mg/dL (men) or \< 55 mg/dL (women)~Exclusion Criteria:~* Current use of or known intolerance to niacin or ezetimibe~* Known history of liver disease (cirrhosis, chronic hepatitis) or abnormal liver associated enzymes, \> 3x the upper laboratory reference value~* Enrollment in another drug or device research protocol~* Females who are pregnant, expect to get pregnant during the course of the study, or are breastfeeding

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Extended release niacin (Type: ACTIVE_COMPARATOR): None
- Ezetimibe (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the pancreas~  * Metastatic disease~ * Not amenable to treatment~ * No localized or locally advanced disease~* Measurable disease (metastatic or primary tumor) defined as ≥ 2 cm by CT scan or ≥ 1 cm by spiral CT scan or MRI~* No progressive thrombo-embolic disease~* No adenocarcinoma of the biliary tract or ampulla of Vater~* No known CNS metastases~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* Life expectancy \> 12 weeks~* ANC ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9 g/dL~* Alkaline phosphatase \< 5 times normal~* Bilirubin \< 1.5 times normal~* Creatinine \< 1.5 times normal~* Creatinine clearance \< 30 mL/min~* Pain controlled or stabilized via analgesic therapy~* Affiliation with social security system~* Not pregnant or nursing~* No controlled or uncontrolled jaundice~* No contraindication to study drugs~* No cardiovascular accident (myocardial infarction, cerebral vascular accident) within the past 6 months~* No serious cardiac and/or respiratory disease~* No other cancer in the past 5 years except the following cancers, provided they have been completely resected:~  * Skin cancer~ * Localized melanoma~ * Carcinoma in situ of the cervix~* No history of thrombophilia~* No history of heparin-induced thrombocytopenia~* No uncontrolled or persistent hypercalcemia~* No psychological, familial, social, and/or geographical condition that precludes participation in the study~PRIOR CONCURRENT THERAPY:~* No prior hematologic therapy for metastatic disease~* No prior abdominal radiotherapy~* No concurrent corticosteroids as anti-emetic therapy~* No other concurrent anticoagulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- chemotherapy (Type: ACTIVE_COMPARATOR): chemotherapy at investigator's discretion
- dalteparin (Type: EXPERIMENTAL): dalteparin: 5000 UI sub-cutaneous injection, from Day 1 to Day 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact Of Antioxidant Micronutrients On Intensive Care Unit (ICU) Outcome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients admitted for above diagnosis assessed on admission by the medical team likely to require more than 48 hours of ICU~Exclusion Criteria:~* absence of consent, participation in another study, liver cirrhosis or major burns and life expectancy \< 24 hours or a lack of commitment to full aggressive care (anticipated withholding or withdrawing treatments in the 48 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- AOX group (Type: EXPERIMENTAL): Treatment group - double dose (loading) for 48 hours then single dose (Se 270 mcg, Zn 30 mg, vit C 1.2 g, B1 100 mg, vit E 300 mg enteral)
- 0 (Type: PLACEBO_COMPARATOR): Group receiving vehicle solution for 5 days (double dose for 48 hours)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficiency of Art-therapy in Psychotic Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* schizophrenia according to DSM IV~Exclusion Criteria:~* addiction problem~* invalidating visual sensory problems~* neurological history

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Art-therapy (Type: EXPERIMENTAL): 16 Art-therapy sessions
- Metacognitive therapy (Type: ACTIVE_COMPARATOR): 16 Metacognitive therapy sessions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cross-Sectional Survey on the Use of Tobacco Products - London (UK)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria (all participants, including IQOS users):~* Legally permitted to buy tobacco products in UK (≥18 years of age).~* Currently residing in the Greater London area.~* Able to read, write and understand English.~* Consent to participate in the survey~Inclusion Criteria (IQOS users only):~* Has used more than 100 HEETS tobacco sticks in his or her lifetime.~* Is currently using IQOS.~* Has access to the internet.~* Is not currently employed by Philip Morris International or any of its affiliates~Exclusion Criteria:~* Not meeting the inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- General Population (Type: None): Adults living in a registered household in the Greater London area.
- IQOS users (Type: None): Adult current IQOS users (at the time of survey) living in the Greater London area who are registered in the UK IQOS User Database and agree to be contacted for research purposes at the time of registration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Effect of Amorphous Calcium Carbonate (ACC) on Healing Time of Distal Radius Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with closed unilateral dorsally angulated fracture of the distal radius (Colles') visible by x-ray.~* Subjects that can begin taking the study treatment exactly 7 (+1) days from the fracture event.~* Subjects treated conservatively by closed reduction and immobilization~* Age 50-90 (inclusive)~* Subjects able to adhere to the visit schedule and protocol requirements and be available to complete the study.~* Subject that had signed the ICF.~Exclusion Criteria:~* Subjects with intra articular fracture or extra-articular fracture that meets the criteria for operative fracture fixation.~* Subjects with pins or plates in the wrist~* Sustained previous fractures or bone surgery in the currently fractured distal forearm~* Subjects with multiple trauma (several fractures at once)~* Subjects suffering from joint diseases that affect the function of the wrist and/or hand of the injured arm.~* Elevated serum calcium (\> 10.2 mg/dL)~* 25-hydroxyvitamin D \< 20 ng/mL~* Subjects suffering from active liver disease or clinical jaundice~* Subjects with current or a history of a malignant neoplasm in the 5 years prior to the study~* Cognitive impairment

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Amorphous calcium carbonate (Type: EXPERIMENTAL): 200 mg elemental calcium tablets, 2 in the morning and 2 in the evening, after a meal
- StarLac (Type: PLACEBO_COMPARATOR): Tablets containing 300 mg StarLac (starch cellulose and lactose blend) to be used as placebo, 2 tablets in the morning and 2 tablets in the evening, after a meal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Buccal Versus Vaginal Misoprostol for Third Trimester Induction of Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willingness to participate / consent in a placebo-controlled trial~* Age 18 and older~* Pregnancy between 34 and 42 years of gestation~* Admitted for labor induction because of either medical, obstetric, or psychosocial indications~* Live singleton fetus~* Bishop score less than or equal to six~* Cephalic presentation~* Reactive non-stress test or Negative contraction test~Exclusion Criteria:~* Premature rupture of membranes~* Multiparity \> 5~* Contraindication to vaginal or labor delivery~* Suspected placental abruption~* Significant hepatic, renal or cardiac disease~* Known hypersensitivity to misoprostol or prostaglandin analogue~* Recent prostaglandin administration for induction of labor~* Multifetal pregnancy~* Macrosomia \> 4500g estimated fetal weight by ultrasound or leopold

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Buccal misoprostol+placebo vaginal pill (Type: EXPERIMENTAL): None
- Vaginal Misoprostol+placebo buccal pill (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. All patients, 18 years of age or older, with advanced cancer are eligible.~2. Patients must have lost 10% in the last 6 months~3. Patients must have a life expectancy of at least 12 weeks.~4. Patients must have a Zubrod performance status of 0-3.~5. Patients must sign an informed consent.~Exclusion Criteria:~1. Patients with symptomatic brain metastases are excluded from this study.~2. Pregnant women or nursing mothers are not eligible for this trial. Patients of child bearing potential must use adequate contraception.~3. Patients with severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections are not eligible for this trial.~4. Patients with head and neck cancers and GI cancers who have functional problems that limits food intake or absorption of nutrients such as partial or complete bowel obstructions, and patients with skin cancers (except melanoma) are not eligible~5. Patients who lost weight on a voluntary diet.~6. Patients who are already taking an appetite stimulant or other anti-depressant, except for SSRI taken in the morning.~7. Patients who had surgery in the last 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Remeron (Mirtazapine) (Type: EXPERIMENTAL): Mirtazapine 15 mg orally at bed time for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues